Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)

NCT01734057 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No eligible patient was enrolled.

Conditions

Purpura
Idiopathic Thrombocytopenic Purpura

Interventions

DRUG: recombinant human thrombopoietin (rhTPO); rituximab
DRUG: Dexamethasone

Sponsor

Shandong University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]